Pharmacogenomic predictors of fingolimod response in relapsing-remitting multiple sclerosis

被引：0

作者：

Campagna, M. P. ^{[1
]}

Stankovich, J. ^{[1
]}

Zhong, M. ^{[1
,2
]}

Kleinova, P. ^{[3
,4
,5
]}

Matesanz, F. ^{[6
]}

Eichau, S. ^{[7
]}

Slee, M. ^{[8
]}

Kilpatrick, T. ^{[9
,10
]}

Kubala Havrdova, E. ^{[11
]}

Izquierdo, G. ^{[7
,11
]}

Patsopoulos, N. ^{[12
]}

Lea, R. ^{[13
]}

Lechner-Scott, J. ^{[14
,15
]}

Butzkueven, H. ^{[1
,2
]}

Jokubaitis, V. ^{[1
,2
]}

机构：

[1] Monash Univ, Cent Clin Sch, Melbourne, Australia

[2] Alfred Hlth, Dept Neurol, Melbourne, Australia

[3] Charles Univ Prague, Fac Med 1, Prague, Czech Republic

[4] Gen Univ Hosp, Dept Neurol, Prague, Czech Republic

[5] Ctr Clin Neurosci, Prague, Czech Republic

[6] Inst Parasitol & Biomed Lopez Neyr, CSIC, Granada, Spain

[7] Hosp Univ Virgen Macarena, Seville, Spain

[8] Flinders Univ S Australia, Coll Med & Publ Hlth, Adelaide, SA, Australia

[9] Melbourne Hlth, Dept Neurol, Melbourne, Australia

[10] Univ Melbourne, Melbourne Neurosci Inst, Melbourne, Australia

[11] Fdn DINAC, Seville, Spain

[12] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA USA

[13] Queensland Univ Technol, Genom Res Ctr, Ctr Genom & Personalised Hlth, Brisbane, Qld, Australia

[14] John Hunter Hosp, Dept Neurol, Newcastle, NSW, Australia

[15] Univ Newcastle, Sch Med & Publ Hlth, Newcastle, NSW, Australia

来源：

MULTIPLE SCLEROSIS JOURNAL | 2022年 / 28卷 / 3_SUPPL期

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

P756

引用

页码：660 / 661

页数：2

共 50 条

[1] Fingolimod for relapsing-remitting multiple sclerosis
La Mantia, Loredana
Tramacere, Irene
Firwana, Belal
Pacchetti, Ilaria
Palumbo, Roberto
Filippini, Graziella
[J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2016, (04):
[2] Predicting response to fingolimod in patients with relapsing-remitting multiple sclerosis
Giuliani, M.
Prosperini, L.
Fanelli, F.
Hirsch, M. N.
De Angelis, F.
Pozzilli, C.
[J]. MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 306 - 306
[3] Oral fingolimod for relapsing-remitting multiple sclerosis
Doggrell, Sheila A.
[J]. EXPERT OPINION ON PHARMACOTHERAPY, 2010, 11 (10) : 1777 - 1781
[4] Effects of fingolimod in relapsing-remitting multiple sclerosis Comment
Sorensen, Per Soelberg
[J]. LANCET NEUROLOGY, 2014, 13 (06): : 526 - 527
[5] ORAL FINGOLIMOD FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS
Vosiliou, S.
[J]. DRUGS OF TODAY, 2010, 46 (05) : 315 - 325
[6] Fingolimod: A Review of Its Use in Relapsing-Remitting Multiple Sclerosis
Mark Sanford
[J]. Drugs, 2014, 74 : 1411 - 1433
[7] Fingolimod: A Review of Its Use in Relapsing-Remitting Multiple Sclerosis
Sanford, Mark
[J]. DRUGS, 2014, 74 (12) : 1411 - 1433
[8] Conjunctival Lymphoma in a Patient on Fingolimod for Relapsing-Remitting Multiple Sclerosis
Christopher, Karen L.
Elner, Victor M.
Demirci, Hakan
[J]. OPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY, 2017, 33 (03): : E73 - E75
[9] Glioblastoma following treatment with fingolimod for relapsing-remitting multiple sclerosis
Sharim, Justin
Tashjian, Randy
Golzy, Nima
Pouratian, Nader
[J]. JOURNAL OF CLINICAL NEUROSCIENCE, 2016, 30 : 166 - 168
[10] Predictors of driving in individuals with relapsing-remitting multiple sclerosis
Akinwuntan, Abiodun Emmanuel
Devos, Hannes
Stepleman, Lara
Casillas, Rhonda
Rahn, Rebecca
Smith, Suzanne
Williams, Mitzi Joi
[J]. MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (03) : 344 - 350

← 1 2 3 4 5 →